» Articles » PMID: 35387663

Assessments of Prolonged Effects of Desflurane and Sevoflurane on Motor Learning Deficits in Aged App Mice

Overview
Journal Mol Brain
Publisher Biomed Central
Date 2022 Apr 7
PMID 35387663
Authors
Affiliations
Soon will be listed here.
Abstract

As the proportion of elderly in society increases, so do the number of older patients undergoing surgical procedures. This is concerning as exposure to anesthesia has been identified as a risk factor for Alzheimer's disease (AD). However, the causal relationship between clinical AD development and anesthesia remains conjectural. Preclinical studies have demonstrated that anesthesia, such as halothane, isoflurane, and sevoflurane, induces AD-like pathophysiological changes and cognitive impairments in transgenic mouse models of AD. Desflurane does not have these effects and is expected to have more potential for use in elderly patients, yet little is known about its effects, especially on non-cognitive functions, such as motor and emotional functions. Thus, we examined the postanesthetic effects of desflurane and sevoflurane on motor and emotional function in aged App (App-KI) mice. This is a recently developed transgenic mouse model of AD exhibiting amyloid β peptide (Aβ) amyloidosis and a neuroinflammatory response in an age-dependent manner without non-physiological amyloid precursor protein (APP) overexpression. Mice were subjected to a short behavioral test battery consisting of an elevated plus maze, a balance beam test, and a tail suspension test seven days after exposure to 8.0% desflurane for 6 h or 2.8% sevoflurane for 2 h. App-KI mice showed significant increments in the percentage of entry and time spent in open arms in the elevated plus maze, increments in the number of slips and latency to traverse for the balance beam test, increments in the limb clasping score, increments in immobile duration, and decrements in latency to first immobile episode for the tail suspension test compared to age-matched wild type (WT) controls. Desflurane- and sevoflurane-exposed App-KI mice showed a delayed decrement in the number of slips for each trial in the balance beam test, while air-treated App-KI mice rapidly improved their performance, and increased their clasping behavior in the tail suspension test. Furthermore, App-KI inhibited the change in membrane GluA3 following exposure to anesthetics in the cerebellum. These results suggest high validity of App-KI mice as an animal model of AD.

Citing Articles

Perinatal choline supplementation prevents learning and memory deficits and reduces brain amyloid Aβ42 deposition in AppNL-G-F Alzheimer's disease model mice.

Bellio T, Laguna-Torres J, Campion M, Chou J, Yee S, Blusztajn J PLoS One. 2024; 19(2):e0297289.

PMID: 38315685 PMC: 10843108. DOI: 10.1371/journal.pone.0297289.

References
1.
Jia Z, Geng L, Xie G, Chu Q, Zhang W . Sevoflurane impairs acquisition learning and memory function in transgenic mice model of Alzheimer's disease by induction of hippocampal neuron apoptosis. Int J Clin Exp Med. 2015; 8(9):15490-7. PMC: 4658928. View

2.
Baranov D, Bickler P, Crosby G, Culley D, Eckenhoff M, Eckenhoff R . Consensus statement: First International Workshop on Anesthetics and Alzheimer's disease. Anesth Analg. 2009; 108(5):1627-30. PMC: 2769511. DOI: 10.1213/ane.0b013e318199dc72. View

3.
Avidan M, Searleman A, Storandt M, Barnett K, Vannucci A, Saager L . Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology. 2009; 111(5):964-70. PMC: 2783989. DOI: 10.1097/ALN.0b013e3181bc9719. View

4.
Cotel M, Jawhar S, Christensen D, Bayer T, Wirths O . Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice. Neurobiol Aging. 2010; 33(1):96-107. DOI: 10.1016/j.neurobiolaging.2010.02.012. View

5.
Feng C, Liu Y, Yuan Y, Cui W, Zheng F, Ma Y . Isoflurane anesthesia exacerbates learning and memory impairment in zinc-deficient APP/PS1 transgenic mice. Neuropharmacology. 2016; 111:119-129. DOI: 10.1016/j.neuropharm.2016.08.035. View